Text and Data Mining valid from 2019-04-09
First Online: 9 April 2019
Compliance with Ethical Standards
: PP received consulting fees from Akebia for work not related to this manuscript. RP-F participated in advisory boards from Akebia and Astra Zeneca and received honoraria from Akebia and AstraZeneca. WCW has received honoraria for unrelated work from Akebia, AMAG Pharma, Amgen, AstraZeneca, Bayer, DaichiiSankyo, Duke Clinical Research Institute, Fibrogen, Relypsa, Vifor Fresenius Medical Care Renal Pharma, and ZS Pharma. BS has participated in clinical trials for the treatment of anaemia on behalf of Akebia. SR, PT-L, and PL are employees of Analysis Group, Inc., a consulting company that received funding from Akebia Therapeutics Inc. to conduct this study. GS is an employee and stockholder of Akebia Therapeutics. AB is a former employee of Akebia and owns Akebia stock and stock options. MS and HBK are employees of Otsuka Pharmaceutical Development & Commercialization, Inc., a collaboration partner of Akebia in the development of vadadustat for the treatment of anaemia secondary to CKD.
: This article does not contain any studies with human participants performed by any of the authors.
: Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.